Ceftizoxime

Ceftizoxime is a third-generation cephalosporin available for parenteral administration.[1] Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subject to metabolism. It was removed from the US Market in 2007.

Ceftizoxime
Clinical data
Trade namesCefizox
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa684043
ATC code
Identifiers
IUPAC name
  • (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.846
Chemical and physical data
FormulaC13H13N5O5S2
Molar mass383.40 g·mol−1

Synthesis

Injectable third generation cephalosporin antibiotic related to cefotaxime, q.v. Exhibits broad spectrum activity and resistance to β-lactamase hydrolysis.

Ceftizoxime synthesis:[2][3]

References
  1. Aldridge KE (1990). "An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria". Clinical Therapeutics. 12 Suppl C: 3–12. PMID 2202509.
  2. DE 2810922, Takaya T, Hisashi T, Kiyoshi T, Toshiyuki C, "New cepham compounds and processes for the production thereof", issued 29 August 1985, assigned to Fujisawa
  3. US 4427674, Takaya T, Hisashi T, Kiyoshi T, Toshiyuki C, "Cephem compounds", issued 24 January 1984, assigned to Fujisawa


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.